Location

Jacksonville, Florida

Contact

Farraye.Francis@mayo.edu Clinical Profile

SUMMARY

Francis (Frank) A. Farraye, M.D., M.S., investigates various aspects of the management of patients with ulcerative colitis and Crohn's disease with particular attention on vaccinations in immunosuppressed patients.

Dr. Farraye and his research team are part of a national consortium called Prevent Covid that examines antibody responses to COVID-19 vaccines in immunocompromised patients with inflammatory bowel disease (IBD). In collaboration with Freddy Caldera, D.O., M.S., from the University of Wisconsin, and Mayo Clinic Division of Immunology's Keith L. Knutson, Ph.D., Dr. Farraye is also investigating T cell responses to COVID-19 vaccines.

Other areas of active research include use of fecal calprotectin in patients with Crohn's disease after ileostomy and efficacy of oral contraceptives in preventing pregnancy in women with Crohn's disease. Dr. Farraye also studies eating disorders in patients with IBD and collaborates with surgeon Luca Stocchi, M.D., in Mayo's Division of Colon and Rectal Surgery, to examine trends in ileal pouch anal surgery in minorities. Dr. Farraye is principal investigator for multiple pharmaceutical trials that offer access to novel agents for patients with refractory IBD.

Focus areas

  • Efficacy and safety of vaccinating patients with ulcerative colitis and Crohn's disease against COVID-19, hepatitis B and shingles
  • Contraceptive options for women with Crohn's disease and menopause in women with IBD
  • Fecal calprotectin as a marker of small bowel inflammation in patients with Crohn's disease and an ileostomy
  • Eating disorders in patients with IBD
  • Trends in the use of ileal pouch anal anastomosis surgery in patients with ulcerative colitis
  • Pharmaceutical trials of novel agents to treat IBD

Significance to patient care

Certain patients with ulcerative colitis and Crohn's disease are at an increased risk of developing infections, several of which may be prevented by vaccination. Dr. Farraye's research on vaccinations in this group of patients have been widely cited and implemented, improving the care delivered to these patients. In addition, the use of a stool-based marker as an alternative to endoscopic and radiologic diagnostics is being explored. Identifying safe and effective methods of contraception allows women with IBD to better control their reproductive health.

Professional highlights

  • Named, Best Doctor, Jacksonville Magazine Best Doctors Issue, 2021
  • Recipient, Joan Cutler Lifetime Achievement Award, Crohn's and Colitis Foundation of America, 2020
  • Recipient, Presidential Poster Award, American College of Gastroenterology, 2018
  • Named, Research Mentor of the Year, Department of Medicine, Boston University, 2013
  • Named, Top Doctor, U.S. News and World Report, 2011

Clinical Studies

See my clinical studies

PUBLICATIONS

See my publications

PROFESSIONAL DETAILS

Primary Appointment

  1. Consultant, Division of Gastroenterology & Hepatology, Department of Internal Medicine

Academic Rank

  1. Professor of Medicine

EDUCATION

  1. MSc Harvard School of Public Health
  2. Clinical Fellowship - Gastroenterology Beth Israel Hospital
  3. Research Fellowship - Gastroenterology Beth Israel Hospital
  4. Residency - Internal Medicine Beth Israel Hospital
  5. Internship - Internal Medicine Beth Israel Hospital
  6. MD Albert Einstein College of Medicine
  7. BS SUNY at Stony Brook
.
BIO-20520437

Mayo Clinic Footer